Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 5, 451-462, May 2006; doi:10.1634/theoncologist.11-5-451
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tarassoff, C. P.
Right arrow Articles by Gulley, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tarassoff, C. P.
Right arrow Articles by Gulley, J. L.

The Community Oncologist

Therapeutic Vaccines for Prostate Cancer

Christopher P. Tarassoff, Philip M. Arlen, James L. Gulley

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Key Words. Prostate cancer • Whole-tumor cell vaccines • Dendritic cells • Poxvirus vaccines • PSA

Correspondence: James L. Gulley, M.D., Ph.D., F.A.C.P., National Cancer Institute, Clinical Immunotherapy Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, 10 Center Drive, MSC 1750, Building 10, Room 5B52, Bethesda, Maryland 20892, USA. Telephone: 301-435-2956; Fax: 301-480-1179; e-mail: GulleyJ{at}mail.nih.gov

Prostate cancer is the most common, noncutaneous cancer for men in the U.S., leading to more than 30,000 deaths a year. Vaccines for prostate cancer, which for several years have been shown to generate immunologic responses, are beginning to show significant clinical promise. At present, numerous therapeutic options are being investigated, including autologous and allogeneic whole-tumor cell vaccines, dendritic cell vaccines, and poxvirus-based vaccines. Advances in basic immunology have translated into new, more complex therapeutic strategies. The findings from current trials and the demonstrated potential to combine vaccines with conventional therapies herald a promising future for the treatment of prostate cancer. This review highlights recent advances and clinical trials in immunotherapy for prostate cancer, along with current thoughts on immunologic and clinical monitoring of these trials.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Wada, K. Yoshimura, E. L. Hipkiss, T. J. Harris, H.-R. Yen, M. V. Goldberg, J. F. Grosso, D. Getnet, A. M. Demarzo, G. J. Netto, et al.
Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model
Cancer Res., May 15, 2009; 69(10): 4309 - 4318.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Gurtler and D. Kaufman
Introduction to the new section.
Oncologist, May 1, 2006; 11(5): 450 - 450.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement